COMP <GO>
PULM vs XBIO // EV/EBITDA & P/E VALUATION
Pulmatrix Inc. (NASDAQ) VS. Xenetic Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: PULM 2
— XBIO 2
■ METRIC PARITY
LAST: $1.42 (-5.67%) • MKT CAP: $5.2M
valuation
—
LAST: $2.12 (+0.95%) • MKT CAP: $5.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PULM VS. XBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PULM | XBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -30.30% | -4.70 | XBIO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 19.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 4/9 | -2.00 | XBIO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.9 | 43.5 | +1.40 | PULM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.2M | $5.0M | $200.4K | PULM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PULM REV | XBIO REV | PULM GROSS % | XBIO GROSS % | PULM FCF | XBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $3.0M | — | — | -$5.4M | -$2.3M |
| FY 2024 | $7.8M | $2.5M | — | — | -$11.1M | -$2.8M |
| FY 2023 | $7.3M | $2.5M | — | — | -$16.0M | -$4.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PULM // BETA —
XBIO // BETA —